Shares of Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 353,940 shares were traded during trading, an increase of 39% from the previous session’s volume of 253,888 shares.The stock last traded at $26.48 and had previously closed at $26.98.
Wall Street Analysts Forecast Growth
Separately, Nomura Securities upgraded Daiichi Sankyo to a “strong-buy” rating in a research report on Friday, June 6th. One investment analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the company currently has a consensus rating of “Strong Buy”.
Read Our Latest Stock Report on Daiichi Sankyo
Daiichi Sankyo Trading Down 3.9%
Daiichi Sankyo Company Profile
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.
Further Reading
- Five stocks we like better than Daiichi Sankyo
- What is the S&P/TSX Index?
- Broadcom Named in Apple’s $100B U.S. Investment Plan
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3 Reasons Salesforce Is a Bargain Right Now
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- How ServiceNow Is Turning AI Strategy Into Real Revenue
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.